Daxor Announces Third Quarter Earnings Ending September 30, 2004.

NEW YORK -- In the release dated November 8, 2004, in the table, the number in the final column of the row titled Net Income (Loss) should read (702,280) (sted 702,280).

The corrected release reads:

DAXOR ANNOUNCES THIRD QUARTER EARNINGS ENDING SEPTEMBER 30, 2004

Daxor Corporation (AMEX: DXR):

Three Months Ended      Nine Months Ended
                            September 30            September 30
                          2004        2003        2004        2003
                      -----------  ----------  ----------  ----------
Total Revenues        $ 1,119,549  $  904,183  $3,183,314  $2,413,467

Net Income (loss)     $   (58,968) $ (180,041) $ (300,665) $ (702,280)

Weighted Average
Number of Shares
Outstanding             4,610,493   4,645,826   4,619,048   4,646,347

Equivalent Share      $     (0.01) $    (0.04) $    (0.06) $    (0.15)

The Company has continued to expand its sales and marketing team for the blood volume analyzer. As of October 31, 2004, kit sales were increased 31% as compared to the comparable 10 months of 2003.

In addition to its sales staff, in the past 4 months the Company has instituted a program of hiring account representatives, whose primary function is to assist institutions in educating their physicians to better understand the benefits of the blood volume analyzer for their patients.

In the past year, there were 3 important papers published on research performed at Columbia Presbyterian Medical Center in New York on the benefits of obtaining a normal blood volume in congestive heart failure patients. The Company anticipates the publication of additional papers in peer review journals about the benefits and accuracy of the blood volume analyzer in the treatment of medical and surgical conditions.

For additional information contact Diane Meegan, Investor Relations, or Stephen Feldschuh, Vice President of Operations.